APGE vs. QGEN, RGEN, PCVX, RVMD, EXEL, CRSP, KRYS, IBRX, IMVT, and SWTX
Should you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), ImmunityBio (IBRX), Immunovant (IMVT), and SpringWorks Therapeutics (SWTX). These companies are all part of the "biological products, except diagnostic" industry.
Qiagen (NYSE:QGEN) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.
Qiagen currently has a consensus price target of $50.95, indicating a potential upside of 17.77%. Apogee Therapeutics has a consensus price target of $73.00, indicating a potential upside of 59.95%. Given Qiagen's stronger consensus rating and higher probable upside, analysts clearly believe Apogee Therapeutics is more favorable than Qiagen.
Qiagen received 229 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 60.79% of users gave Qiagen an outperform vote.
Qiagen has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
In the previous week, Apogee Therapeutics had 1 more articles in the media than Qiagen. MarketBeat recorded 6 mentions for Apogee Therapeutics and 5 mentions for Qiagen. Qiagen's average media sentiment score of 1.02 beat Apogee Therapeutics' score of 0.97 indicating that Apogee Therapeutics is being referred to more favorably in the news media.
Qiagen has a net margin of 17.38% compared to Qiagen's net margin of 0.00%. Apogee Therapeutics' return on equity of 12.59% beat Qiagen's return on equity.
70.0% of Qiagen shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 36.1% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Qiagen and Apogee Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Apogee Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apogee Therapeutics Competitors List
Related Companies and Tools
